Pharaoh Neuro develops the Neurapheresis™ platform, an extracorporeal system that precisely manages cerebrospinal fluid (CSF) to restore its balance and protect brain health in neurocritical patients. By filtering blood and metabolic waste from the CSF through a spinal catheter extension, the technology aims to improve outcomes in conditions such as aneurysmal subarachnoid hemorrhage, as evaluated in the ongoing PILLAR‑XT trial.
Funding
Funding not disclosed
Founders
Product
Problem
Neurocritical care patients often experience disrupted cerebrospinal fluid (CSF) balance, leading to elevated intracranial pressure, accumulation of blood and its breakdown products, and impaired waste clearance, which can worsen brain injury and increase mortality.
Solution
Pharaoh Neuro’s Neurapheresis™ platform is an extracorporeal system that continuously filters cerebrospinal fluid to remove blood, hemolysis by‑products, and excess metabolites while maintaining physiological pressure. By precisely managing CSF composition, the device aims to restore intracranial pressure equilibrium and protect neuronal tissue. Clinical evaluation in the Pillar‑XT trial for aneurysmal subarachnoid hemorrhage demonstrated safety, tolerability, and effective filtration of harmful substances. The system integrates a spinal catheter extension for CSF access with a closed‑loop filtration circuit, enabling real‑time monitoring and adjustment of CSF parameters. This approach targets the root cause of CSF imbalance rather than merely treating downstream symptoms.
Target Audience
Primary customers are neurocritical care units in hospitals and specialized intensive care centers that treat patients with subarachnoid hemorrhage, traumatic brain injury, and other conditions causing CSF imbalance.
Features
- Extracorporeal filtration circuit designed specifically for cerebrospinal fluid
- Spinal catheter extension for minimally invasive CSF access in neurocritical patients
- Continuous removal of blood, hemolysis products, and metabolic waste from CSF
- Real‑time pressure monitoring and automated regulation to maintain intracranial pressure homeostasis
- Closed‑loop system with biocompatible filters to ensure sterility and safety during prolonged therapy
- Clinical data from the Pillar‑XT trial supporting safety, tolerability, and filtration efficacy